Recognized as the original and leading annual forum for personalized medicine

Attracts recognized authorities and experts across healthcare and biotechnology sectors

Delivers the broadest and most up-to-date content across all facets of precision medicine in a collegial atmosphere.

Recognized as the original and leading annual forum for precision medicine

Attracts recognized authorities and experts across healthcare and biotechnology sectors

Delivers the broadest and most up-to-date content across all facets of precision medicine in a collegial atmosphere.

2009

Established

8,500

Attendees

1,250

Speakers

750

Companies
Intermountain Healthcare

“PMWC has created an outstanding forum that touches every component of precision medicine and convenes all of its stakeholders.

I am honored to be part of this experience and to be able to influence the structure and focus of the upcoming PMWC 2017 SV conference.”

Keith Yamamoto, PhD, PMWC 2017 Silicon Valley Program Chair

Professor UCSF, Vice Chancellor for Science Policy and Strategy, Vice Dean for Research, School of Medicine

How To Engage Community Oncologists in Precision Medicine   Session Chair: Lincoln Nadauld, Intermountain Health Care; Laurence Marton, PMWC 2014 Program Chair

How To Engage Community Oncologists in Precision Medicine

Session Chair: Lincoln Nadauld, Intermountain Health Care; Laurence Marton, PMWC 2014 Program Chair

Immunotherapy: Emerging applications and therapies    Session Chair: James Allison, MD Anderson Cancer Center

Immunotherapy: Emerging applications and therapies

Session Chair: James Allison, MD Anderson Cancer Center

Rare Disease   Session Chair: Nick Lench, Congenica Ltd

Rare Disease

Session Chair: Nick Lench, Congenica Ltd

Clinical Trials in Immunotherapy   Session Chair: Patrice Hugo, Q2 Solutions

Clinical Trials in Immunotherapy

Session Chair: Patrice Hugo, Q2 Solutions

Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology   Session Chair: Brad Gray, NanoString Technologies

Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology

Session Chair: Brad Gray, NanoString Technologies

Generating Insights from Multi-modal Healthcare Data for Precision Medicine   Session Chair: Atul Butte, UCSF

Generating Insights from Multi-modal Healthcare Data for Precision Medicine

Session Chair: Atul Butte, UCSF

Issues and Challenges of Immunotherapy   Session Chair: Larry Corey, Fred Hutchinson Cancer Research Center

Issues and Challenges of Immunotherapy

Session Chair: Larry Corey, Fred Hutchinson Cancer Research Center

The Last Clinical Mile of Precision Medicine – Challenges at the Point of Care   Session Chair: Assaf Halevy, 2bPrecise

The Last Clinical Mile of Precision Medicine – Challenges at the Point of Care

Session Chair: Assaf Halevy, 2bPrecise

Real-world Solutions to Practical Challenges When Implementing Precision Medicine Programs   Session Chair: Chris Cournoyer, N-of-One

Real-world Solutions to Practical Challenges When Implementing Precision Medicine Programs

Session Chair: Chris Cournoyer, N-of-One

Emerging Technologies Hold Promise to Inform the Practice of Precision Medicine   Session Chair: John Ryals, Metabolon

Emerging Technologies Hold Promise to Inform the Practice of Precision Medicine

Session Chair: John Ryals, Metabolon

Update on Government Initiatives: The PMI, Cancer Moonshot, and Microbiome Initiative   Session Chair: Eric Dishman, NIH

Update on Government Initiatives: The PMI, Cancer Moonshot, and Microbiome Initiative

Session Chair: Eric Dishman, NIH

Unlocking Real-World Clinical Data   Session Chair: Amy Abernethy, Flatiron Health; Cary P. Gross, Yale University

Unlocking Real-World Clinical Data

Session Chair: Amy Abernethy, Flatiron Health; Cary P. Gross, Yale University

Immunotherapy: Immunocheckpoint Inhibitors & Beyond   Session Chair: Irv Weissman, Stanford School of Medicine

Immunotherapy: Immunocheckpoint Inhibitors & Beyond

Session Chair: Irv Weissman, Stanford School of Medicine

Emerging Themes in the Human Microbiome   Session Chair: Michael Fischbach, UCSF

Emerging Themes in the Human Microbiome

Session Chair: Michael Fischbach, UCSF

Expanding the Reach of Genomic Analysis   Session Chair: Deanna Church, 10x Genomics

Expanding the Reach of Genomic Analysis

Session Chair: Deanna Church, 10x Genomics

Personalized Medicine Patent Law Update   Session Chairs: Catherine Polizzi, Morrison and Foerster and Michael Shuster, Fenwick & West

Personalized Medicine Patent Law Update

Session Chairs: Catherine Polizzi, Morrison and Foerster and Michael Shuster, Fenwick & West

New Healthcare Paradigm from the $100 Genome   Session Chair:  Yiwu He, BGI

New Healthcare Paradigm from the $100 Genome

Session Chair: Yiwu He, BGI

Beyond Genomics for Predicting Patient Response   Session Chair: Parker Cassidy, Mitra Biotech

Beyond Genomics for Predicting Patient Response

Session Chair: Parker Cassidy, Mitra Biotech

Building Value for Liquid Biopsies in Oncology   Session Chair: Frederic Pla, Genomic Health

Building Value for Liquid Biopsies in Oncology

Session Chair: Frederic Pla, Genomic Health

Large Scale Human Genetics in Genomic Medicine and Drug Discovery   Session Chair: Aris Baris, Regeneron

Large Scale Human Genetics in Genomic Medicine and Drug Discovery

Session Chair: Aris Baris, Regeneron

Rare Disease Drug Development is Personalized Medicine   Session Chair: Mary Dixon Drake, Innovenn

Rare Disease Drug Development is Personalized Medicine

Session Chair: Mary Dixon Drake, Innovenn

Clinical Next-Gen Sequencing for Infectious Disease Diagnosis   Session Chair: Charles Chiu, UCSF

Clinical Next-Gen Sequencing for Infectious Disease Diagnosis

Session Chair: Charles Chiu, UCSF

Diagnostics Policy and the Impact on Innovation   Session Chair: Michael W. Nall, Biocept

Diagnostics Policy and the Impact on Innovation

Session Chair: Michael W. Nall, Biocept

Pathogen Specific Biologics for Infectious Diseases   Session Chair: Steven J. Projan, Medimmune

Pathogen Specific Biologics for Infectious Diseases

Session Chair: Steven J. Projan, Medimmune

Importance of Standardized Assays for Precision Medicine   Session Chair: Jeffrey Edward Miller, Invivoscribe

Importance of Standardized Assays for Precision Medicine

Session Chair: Jeffrey Edward Miller, Invivoscribe

Complementary use of Digital PCR and NGS in Cancer Liquid Biopsy   Session Chair: George Karlin-Neumann, BioRad

Complementary use of Digital PCR and NGS in Cancer Liquid Biopsy

Session Chair: George Karlin-Neumann, BioRad

Moving Personalized Medicine to Personalized Health   Session Chair: Harold L. Paz, Aetna

Moving Personalized Medicine to Personalized Health

Session Chair: Harold L. Paz, Aetna

Clinical Applications of ctDNA in Cancer Management   Session Chair: Clive Morris, Inivata

Clinical Applications of ctDNA in Cancer Management

Session Chair: Clive Morris, Inivata

The Economics of Bringing Precision Medicine to the Clinic   Session Chair: George Poste, ASU

The Economics of Bringing Precision Medicine to the Clinic

Session Chair: George Poste, ASU

Next-Generation Liquid Biopsy Testing: Promise and Limitations   Session Chair: Jason Myers, ArcherDX

Next-Generation Liquid Biopsy Testing: Promise and Limitations

Session Chair: Jason Myers, ArcherDX

Genetic Testing In Healthy Population   Session Chair: Randy Scott, Invitae

Genetic Testing In Healthy Population

Session Chair: Randy Scott, Invitae

Emerging Infections: Tracking, Testing and Public Health Response   Session Chair: Steve Miller, UCSF

Emerging Infections: Tracking, Testing and Public Health Response

Session Chair: Steve Miller, UCSF

Advancing the Clinic with Emerging NGS Technologies   Session Chair: Clive Brown, Oxford Nanopore

Advancing the Clinic with Emerging NGS Technologies

Session Chair: Clive Brown, Oxford Nanopore

How To Engage Community Oncologists in Precision Medicine   Session Chair: Lincoln Nadauld, Intermountain Health Care; Laurence Marton, PMWC 2014 Program Chair

How To Engage Community Oncologists in Precision Medicine

Session Chair: Lincoln Nadauld, Intermountain Health Care; Laurence Marton, PMWC 2014 Program Chair

Immunotherapy: Emerging applications and therapies    Session Chair: James Allison, MD Anderson Cancer Center

Immunotherapy: Emerging applications and therapies

Session Chair: James Allison, MD Anderson Cancer Center

Rare Disease   Session Chair: Nick Lench, Congenica Ltd

Rare Disease

Session Chair: Nick Lench, Congenica Ltd

Clinical Trials in Immunotherapy   Session Chair: Patrice Hugo, Q2 Solutions

Clinical Trials in Immunotherapy

Session Chair: Patrice Hugo, Q2 Solutions

Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology   Session Chair: Brad Gray, NanoString Technologies

Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology

Session Chair: Brad Gray, NanoString Technologies

Generating Insights from Multi-modal Healthcare Data for Precision Medicine   Session Chair: Atul Butte, UCSF

Generating Insights from Multi-modal Healthcare Data for Precision Medicine

Session Chair: Atul Butte, UCSF

Issues and Challenges of Immunotherapy   Session Chair: Larry Corey, Fred Hutchinson Cancer Research Center

Issues and Challenges of Immunotherapy

Session Chair: Larry Corey, Fred Hutchinson Cancer Research Center

The Last Clinical Mile of Precision Medicine – Challenges at the Point of Care   Session Chair: Assaf Halevy, 2bPrecise

The Last Clinical Mile of Precision Medicine – Challenges at the Point of Care

Session Chair: Assaf Halevy, 2bPrecise

Real-world Solutions to Practical Challenges When Implementing Precision Medicine Programs   Session Chair: Chris Cournoyer, N-of-One

Real-world Solutions to Practical Challenges When Implementing Precision Medicine Programs

Session Chair: Chris Cournoyer, N-of-One

Emerging Technologies Hold Promise to Inform the Practice of Precision Medicine   Session Chair: John Ryals, Metabolon

Emerging Technologies Hold Promise to Inform the Practice of Precision Medicine

Session Chair: John Ryals, Metabolon

Update on Government Initiatives: The PMI, Cancer Moonshot, and Microbiome Initiative   Session Chair: Eric Dishman, NIH

Update on Government Initiatives: The PMI, Cancer Moonshot, and Microbiome Initiative

Session Chair: Eric Dishman, NIH

Unlocking Real-World Clinical Data   Session Chair: Amy Abernethy, Flatiron Health; Cary P. Gross, Yale University

Unlocking Real-World Clinical Data

Session Chair: Amy Abernethy, Flatiron Health; Cary P. Gross, Yale University

Immunotherapy: Immunocheckpoint Inhibitors & Beyond   Session Chair: Irv Weissman, Stanford School of Medicine

Immunotherapy: Immunocheckpoint Inhibitors & Beyond

Session Chair: Irv Weissman, Stanford School of Medicine

Emerging Themes in the Human Microbiome   Session Chair: Michael Fischbach, UCSF

Emerging Themes in the Human Microbiome

Session Chair: Michael Fischbach, UCSF

Expanding the Reach of Genomic Analysis   Session Chair: Deanna Church, 10x Genomics

Expanding the Reach of Genomic Analysis

Session Chair: Deanna Church, 10x Genomics

Personalized Medicine Patent Law Update   Session Chairs: Catherine Polizzi, Morrison and Foerster and Michael Shuster, Fenwick & West

Personalized Medicine Patent Law Update

Session Chairs: Catherine Polizzi, Morrison and Foerster and Michael Shuster, Fenwick & West

New Healthcare Paradigm from the $100 Genome   Session Chair:  Yiwu He, BGI

New Healthcare Paradigm from the $100 Genome

Session Chair: Yiwu He, BGI

Beyond Genomics for Predicting Patient Response   Session Chair: Parker Cassidy, Mitra Biotech

Beyond Genomics for Predicting Patient Response

Session Chair: Parker Cassidy, Mitra Biotech

Building Value for Liquid Biopsies in Oncology   Session Chair: Frederic Pla, Genomic Health

Building Value for Liquid Biopsies in Oncology

Session Chair: Frederic Pla, Genomic Health

Large Scale Human Genetics in Genomic Medicine and Drug Discovery   Session Chair: Aris Baris, Regeneron

Large Scale Human Genetics in Genomic Medicine and Drug Discovery

Session Chair: Aris Baris, Regeneron

Rare Disease Drug Development is Personalized Medicine   Session Chair: Mary Dixon Drake, Innovenn

Rare Disease Drug Development is Personalized Medicine

Session Chair: Mary Dixon Drake, Innovenn

Clinical Next-Gen Sequencing for Infectious Disease Diagnosis   Session Chair: Charles Chiu, UCSF

Clinical Next-Gen Sequencing for Infectious Disease Diagnosis

Session Chair: Charles Chiu, UCSF

Diagnostics Policy and the Impact on Innovation   Session Chair: Michael W. Nall, Biocept

Diagnostics Policy and the Impact on Innovation

Session Chair: Michael W. Nall, Biocept

Pathogen Specific Biologics for Infectious Diseases   Session Chair: Steven J. Projan, Medimmune

Pathogen Specific Biologics for Infectious Diseases

Session Chair: Steven J. Projan, Medimmune

Importance of Standardized Assays for Precision Medicine   Session Chair: Jeffrey Edward Miller, Invivoscribe

Importance of Standardized Assays for Precision Medicine

Session Chair: Jeffrey Edward Miller, Invivoscribe

Complementary use of Digital PCR and NGS in Cancer Liquid Biopsy   Session Chair: George Karlin-Neumann, BioRad

Complementary use of Digital PCR and NGS in Cancer Liquid Biopsy

Session Chair: George Karlin-Neumann, BioRad

Moving Personalized Medicine to Personalized Health   Session Chair: Harold L. Paz, Aetna

Moving Personalized Medicine to Personalized Health

Session Chair: Harold L. Paz, Aetna

Clinical Applications of ctDNA in Cancer Management   Session Chair: Clive Morris, Inivata

Clinical Applications of ctDNA in Cancer Management

Session Chair: Clive Morris, Inivata

The Economics of Bringing Precision Medicine to the Clinic   Session Chair: George Poste, ASU

The Economics of Bringing Precision Medicine to the Clinic

Session Chair: George Poste, ASU

Next-Generation Liquid Biopsy Testing: Promise and Limitations   Session Chair: Jason Myers, ArcherDX

Next-Generation Liquid Biopsy Testing: Promise and Limitations

Session Chair: Jason Myers, ArcherDX

Genetic Testing In Healthy Population   Session Chair: Randy Scott, Invitae

Genetic Testing In Healthy Population

Session Chair: Randy Scott, Invitae

Emerging Infections: Tracking, Testing and Public Health Response   Session Chair: Steve Miller, UCSF

Emerging Infections: Tracking, Testing and Public Health Response

Session Chair: Steve Miller, UCSF

Advancing the Clinic with Emerging NGS Technologies   Session Chair: Clive Brown, Oxford Nanopore

Advancing the Clinic with Emerging NGS Technologies

Session Chair: Clive Brown, Oxford Nanopore

Testimonials

“PMWC has proven, time and time again, that it attracts thought-leaders from all the relevant fields and catalyzes crucial collaboration through inspiring and practical program content. This is the Conference for entrepreneurs to meet payors, and for researchers to connect with service providers and for clinicians to hear from leading providers.”

Lee Hood, PhD, MD

President, Institute for Systems Biology

“PMWC provides a valuable insight for physicians and others who may be wondering how close we are getting to realizing the arrival of personalized medicine. The conferences are helpful in understanding where and how the envelope is being pushed.”

Peter Paul Yu, MD, FACP, FASCO

Immediate Past President, ASCO

“PMWC is a very well organized conference based in Silicon Valley that addresses all of the salient issues facing personalized medicine and offers emerging personalized medicine companies a chance to showcase their latest innovations, reminding us how exciting the field is.”

Ed Abrahams, PhD

President, PMC